Somatrogon

Somatrogon (somatrogon-ghla; CAS 1663481-09-1; approximate molecular weight 40 kDa including glycosylation) is a long-acting recombinant human growth hormone receptor agonist produced in Chinese hamster ovary cells by recombinant DNA technology and approved for the treatment of pediatric growth hormone deficiency as a once-weekly subcutaneous injection. The molecule comprises the complete 191-amino-acid sequence of native human growth hormone with one copy of the 28-amino-acid C-terminal peptide (CTP) from the beta-subunit of human chorionic gonadotropin fused at the N-terminus and two tandem copies of CTP fused at the C-terminus [1, 2]. The CTP cassettes introduce O-linked glycosylation sites that reduce renal clearance, extend the circulating half-life from the 2 to 4 hours of native somatropin to an effective half-life of approximately 28 to 38 hours, and thereby permit once-weekly dosing at 0.66 mg/kg without loss of growth-promoting efficacy relative to daily somatropin [3, 4]. Somatrogon binds the homodimeric growth hormone receptor and activates the JAK2-STAT5b signaling cascade, producing downstream increases in hepatic and peripheral insulin-like growth factor 1 (IGF-1) synthesis, skeletal longitudinal growth, protein anabolism, and modulation of carbohydrate and lipid metabolism identical in pathway to native growth hormone [5, 6]. The pivotal global Phase 3 clinical trial (NCT02968004) randomized 224 treatment-naive prepubertal children with growth hormone deficiency to once-weekly somatrogon (0.66 mg/kg) or once-daily somatropin (Genotropin, 0.24 mg/kg/week) for 12 months and demonstrated non-inferiority of somatrogon on the primary endpoint of annualized height velocity (somatrogon 10.12 cm/year versus somatropin 9.78 cm/year), with height standard deviation score improvements numerically favoring the somatrogon arm [7]. A parallel Phase 3 study in Japanese children confirmed non-inferiority with consistent safety [8]. Long-term extension data through 5 years of treatment demonstrated sustained catch-up growth with a mean height standard deviation score increase from baseline of 1.94 at extension year 4, consistent with durable efficacy [9]. The safety profile is characterized by injection site reactions (pain in 39.4 percent of somatrogon recipients versus 25.2 percent of somatropin recipients), nasopharyngitis, headache, pyrexia, and the pharmacological class effects of growth hormone therapy including transient hyperglycemia, hypothyroidism unmasking, and benign intracranial hypertension [7, 10]. Immunogenicity is notable: 77.1 percent of somatrogon-treated subjects developed anti-drug antibodies during the 12-month pivotal trial versus 15.6 percent of somatropin-treated subjects, but neutralizing antibody activity was not detected, and anti-drug antibodies did not have a clinically significant impact on efficacy or safety through 42 months of observation [7, 11]. Somatrogon received marketing authorization from the European Medicines Agency in January 2022, from Health Canada in December 2021, from the Australian Therapeutic Goods Administration in 2021, and from the United States Food and Drug Administration on June 27, 2023, following an initial complete response letter in January 2022 that required supplementary manufacturing data [12, 13]. The compound is marketed as Ngenla in a prefilled pen presentation requiring no reconstitution. This monograph reviews the molecular design, CTP-based half-life extension technology, growth hormone receptor pharmacology, comprehensive pharmacokinetic characterization, the pediatric clinical evidence base, sourcing and handling considerations, drug interaction profile, adverse event and immunogenicity data, and a structured comparative assessment of five alternative growth hormone preparations against somatrogon on five competency standards.